Lee Anbok, Won Kyu Yeoun, Lim Sung-Jig, Cho Sun Young, Han Sang-Ah, Park SaeGwang, Song Jeong-Yoon
Department of Surgery, Busan Paik Hospital, INJE University, College of Medicine, Busan, Republic of Korea.
Department of Pathology, Kyung Hee University Hospital at Gangdong, Kyung Hee University, College of Medicine, Seoul, Republic of Korea.
Pathol Res Pract. 2018 May;214(5):619-624. doi: 10.1016/j.prp.2018.04.006. Epub 2018 Apr 18.
Many studies have reported that Aldehyde dehydrogenase 1 (ALDH1) and tumor-infiltrating lymphocytes (TIL) are related to breast cancer prognosis. However, the clinical significance of ALDH1 and tumor-infiltrating immune cells in breast cancer has not been fully investigated in patients who received neoadjuvant chemotherapy (NAC). We studied the significance of the expression of ALDH1 and the population of TIL for predicting the prognosis and chemotherapeutic response of patients with breast cancer who had received NAC. Forty patients who underwent NAC were enrolled in this study. ALDH1 and TIL (T cells and tumor associated macrophages) were evaluated before and after NAC. The influences of ALDH1 expression status and TIL populations on both prognosis and chemotherapeutic response were evaluated. ALDH1 positivity was related to estrogen receptor (p = 0.026) and progesterone receptor negativity (p = 0.025). Positive change of ALDH1 after NAC tended to be associated with a poor NAC response (p = 0.078). Patients with more CD8+ T cells before NAC and fewer CD68 (+) macrophages after NAC tended to have better OS, respectively (p = 0.086, p = 0.096). The chemotherapeutic response and prognosis of patients with breast cancer who received NAC are thought to be determined by the tumor microenvironment. Further research with more patients and a longer study period is needed.
许多研究报告称，醛脱氢酶1（ALDH1）和肿瘤浸润淋巴细胞（TIL）与乳腺癌预后相关。然而，在接受新辅助化疗（NAC）的患者中，ALDH1和肿瘤浸润免疫细胞在乳腺癌中的临床意义尚未得到充分研究。我们研究了ALDH1表达及TIL数量对于预测接受NAC的乳腺癌患者的预后和化疗反应的意义。40例接受NAC的患者纳入本研究。在NAC前后评估ALDH1和TIL（T细胞和肿瘤相关巨噬细胞）。评估ALDH1表达状态和TIL数量对预后和化疗反应的影响。ALDH1阳性与雌激素受体（p = 0.026）和孕激素受体阴性（p = 0.025）相关。NAC后ALDH1的阳性变化往往与NAC反应不佳相关（p = 0.078）。NAC前CD8 + T细胞较多且NAC后CD68（+）巨噬细胞较少的患者往往分别具有更好的总生存期（p = 0.086，p = 0.096）。接受NAC的乳腺癌患者的化疗反应和预后被认为由肿瘤微环境决定。需要更多患者和更长研究周期的进一步研究。
